ArticleCurrent medicinal chemistry2026
Knockdown of FKBP12.6 may Cause Bladder Dysfunction in Mice by Affecting IP3R/TRPM4 Function.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFKBP12.6 is a crucial calcium regulatory molecule involved in the regulation of bladder excitatory contraction. This study employed FKBP12.6 knockout mice to investigate the impact of FKBP12.6 on the expression and function of IP3R/TRPM4 and its subsequent effect on bladder contraction function.
methodsThe study selected 129S2/SvPasCrl and FKBP12.6 knockout mice and constructed a Partial Bladder Outlet Obstruction (PBOO) mouse model. GSE1595 data were utilized to analyze calcium signaling pathway changes. Void spot assays, urodynamic tests, and visceromotor response were employed to evaluate bladder function, while HE staining was used to assess bladder morphology. Immunofluorescence, co-immunoprecipitation, and Western blot techniques were employed to detect the localization, expression, and binding changes of FKBP12.6, Inositol-1,4,5 trisphosphate Receptor (IP3R), and TRPM4.
resultsFKBP12.6 was significantly downregulated in PBOO mice (0.9998±0.07 vs. 0.2911±0.04; p <0.05). The micturition frequency (31.42±4.93 vs. 12.17±3.186), bladder sensitivity (1.59 ± 0.22 vs. 3.57± 0.43; p<0.01), detrusor instability, and muscle strip sensitivity (3.470.51 vs. 5.77±0.35; p<0.01) were increased significantly in FKBP12.6 Knockout (KO) mice (p <0.05). FKBP12.6 knockout did not affect the expressions of IP3R and TRPM4 proteins, but FKBP12.6 directly bound to IP3R in mouse bladder detrusor. IP3R/TRPM4 pathway inhibitors, 2-APB and 9-PHE, notably inhibited detrusor sensitivity, micturition frequency, and urination urgency in FKBP12.6 KO mice.
conclusionThe expression of FKBP12.6 was decreased in the bladder of PBOO mice, and the deletion of FKBP12.6 may lead to bladder dysfunction in mice by affecting the functional activity of IP3R/TRPM4.
Indexed as
Identifiers
40051354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.